These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 16213290)

  • 41. Influence of induction therapy on rejection and survival in heart transplantation.
    Almenar L; García-Palomar C; Martínez-Dolz L; Chamorro C; Moro J; Zorio E; Arnau MA; Rueda J; Osa A; Cardo ML
    Transplant Proc; 2005 Nov; 37(9):4024-7. PubMed ID: 16386616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Successful treatment of 115 pediatric renal transplant recipients with tacrolimus-based immunosuppressive therapy: a 7-year multicenter study in Japan.
    Hasegawa A; Oshima S; Takahashi K; Uchida K; Ito K; Sonoda T
    Transplant Proc; 2005 May; 37(4):1769-70. PubMed ID: 15919460
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3?
    Dé P; Bechstein WO; Blumhardt G; Lange D; Schattenfroh N; Neuhaus P
    Transplant Proc; 1993 Aug; 25(4):2693-4. PubMed ID: 7689279
    [No Abstract]   [Full Text] [Related]  

  • 44. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients.
    Toyoda M; Galfayan K; Wachs K; Czer L; Jordan SC
    Clin Transplant; 1995 Dec; 9(6):472-80. PubMed ID: 8645891
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lipopolysaccharide-binding protein as a new and reliable infection marker after kidney transplantation.
    Kaden J; Zwerenz P; Lambrecht HG; Dostatni R
    Transpl Int; 2002 Apr; 15(4):163-72. PubMed ID: 11976738
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Delayed use of OKT3 for severe acute tubular necrosis in renal transplantation.
    VanderWerf BA
    Transplant Proc; 1996 Aug; 28(4):2115-6. PubMed ID: 8769172
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of renal allograft acute rejection with methylprednisolone: effect of fixed dose versus dose per body mass index.
    Douzdjian V; Rice JC; Gugliuzza KK; Fisch JC; Carson RW
    Clin Transplant; 1996 Jun; 10(3):310-5. PubMed ID: 8826672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. OKT3 for the treatment of steroid-resistant acute renal allograft rejection.
    Jogose JT; Bailey RR; Lynn KL; Robson RA; Wells JE
    Nephron; 1997; 77(3):298-303. PubMed ID: 9375823
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Infectious complications in kidney transplant recipients: a single-center experience.
    Charfeddine K; Zaghden S; Kharrat M; Kamoun K; Jarraya F; Hachicha J
    Transplant Proc; 2005; 37(6):2823-5. PubMed ID: 16182820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The influence of the immunosuppressants OKT3 and ATG on immunological parameters.
    Neumann MC; Müller TF; Sprenger H; Gemsa D; Lange H
    Clin Nephrol; 1996 May; 45(5):345-8. PubMed ID: 8738669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [OKT3 for recipients with steroid-resistant acute rejection after liver transplantation].
    Wu LW; He XS; Zhu XF; Wang DP; Ju WQ; Tai Q; Huang JF
    Zhonghua Gan Zang Bing Za Zhi; 2007 Nov; 15(11):857-8. PubMed ID: 18073076
    [No Abstract]   [Full Text] [Related]  

  • 52. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants.
    Kee TY; Chapman JR; O'Connell PJ; Fung CL; Allen RD; Kable K; Vitalone MJ; Nankivell BJ
    Transplantation; 2006 Jul; 82(1):36-42. PubMed ID: 16861939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. OKT3 treatment of cardiac allograft rejection.
    Haverty TP; Sanders M; Sheahan M
    J Heart Lung Transplant; 1993; 12(4):591-8. PubMed ID: 8369321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
    Troncoso P; Ortiz AM; Jara A; Vilches S
    Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of microvascular injury on steroid and OKT3 response in renal allograft rejection.
    Ozdemir BH; Demirhan B; Ozdemir FN; Dalgiç A; Haberal M
    Transplantation; 2004 Sep; 78(5):734-40. PubMed ID: 15371678
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Murine monoclonal CD3 antibody (OKT3)-based early rejection prophylaxis in pediatric heart transplantation.
    Shaddy RE; Bullock EA; Morwessel NJ; Hannon DW; Renlund DG; Karwande SV; McGough EC; Hawkins JA
    J Heart Lung Transplant; 1993; 12(3):434-9. PubMed ID: 8329414
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection.
    Kamath S; Dean D; Peddi VR; Schroeder TJ; Alexander JW; Cavallo T; First MR
    Transplantation; 1997 Nov; 64(10):1428-32. PubMed ID: 9392306
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection.
    Midtvedt K; Tafjord AB; Hartmann A; Eide TC; Holdaas H; Nordal KP; Draganov B; Sødal G; Leivestad T; Fauchald P
    Transplantation; 1996 Jul; 62(1):38-42. PubMed ID: 8693541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of acute rejection of kidney allograft.
    Yu LX; Jia YB; Zhang Y
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Aug; 22(8):752-4. PubMed ID: 12376272
    [TBL] [Abstract][Full Text] [Related]  

  • 60. OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease.
    Knop S; Hebart H; Gscheidle H; Holler E; Kolb HJ; Niederwieser D; Einsele H
    Bone Marrow Transplant; 2005 Nov; 36(9):831-7. PubMed ID: 16151429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.